Engineered α/β-Hybrid Peptides with Enhanced Cancer Selectivity and Antimicrobial Activity | Research

The takeaway

N-terminal modified α/β-hybrid peptides showed enhanced selectivity between cancer and normal cells while maintaining potent antimicrobial activity through engineered backbone modifications.

Selective by design
Engineering the peptide backbone chemistry enhanced cancer cell selectivity while maintaining bacteria-killing ability — precision through chemistry

What the researchers found

N-terminal modified α/β-hybrid peptides: enhanced cancer vs normal cell selectivity + maintained antimicrobial activity through backbone engineering.

Why it matters

Selectivity is the key challenge for peptide therapeutics. Engineering backbone chemistry to enhance cancer selectivity enables safer dual-function drugs.

How the study worked

Design and synthesis of α/β-hybrid peptides with N-terminal modifications, selectivity testing (cancer vs normal cells), and antimicrobial activity assessment.

What this study cannot tell us

In vitro selectivity. In vivo validation needed.

How to read the evidence

Rational design study with selectivity characterization.

When this study was published

Published in 2025.

The bigger picture

Backbone engineering of hybrid peptides is a powerful strategy for fine-tuning selectivity across antimicrobial and anticancer applications.

Questions still open

Would α/β-hybrid stability improvements persist in vivo?
Can selectivity be further enhanced with additional backbone modifications?
Would these hybrids resist proteolytic degradation better than all-α peptides?

Common questions

What are hybrid peptides?

Peptides made from a mix of natural (α) and modified (β) amino acids. The modified backbone makes them more stable and selective — better at targeting cancer cells while sparing healthy ones.

Why is selectivity important?

The ideal cancer drug kills cancer but not healthy cells. These backbone-engineered peptides achieve better selectivity than natural peptides, making them safer for potential clinical use.

Read the original research

Engineered N-terminal modified α/β-hybrid peptides with enhanced selectivity and stability: Multi-target antibacterials for combating MRSA.

Bioorganic chemistry, 170, 109495

View on PubMed ↗Publisher’s paper ↗

Citation

Kumari, Jyoti; Sarkar, Aminur Rahman; Rashid, Beenish; Rathore, Arti; Firdous, Shifa; Chowdhary, Rubina; Sarkar, Biplab; Manhas, Rakshit; Rai, Rajkishor; Mahapa, Avisek. (2026). Engineered N-terminal modified α/β-hybrid peptides with enhanced selectivity and stability: Multi-target antibacterials for combating MRSA.. Bioorganic chemistry, 170, 109495. https://doi.org/10.1016/j.bioorg.2026.109495